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Soluble Guanylyl Cyclase (sGC) is an obligatory het-
erodimeric protein (α/β), which is activated by Nitric
Oxide (NO) and mediates a wide variety of NO physio-
logical functions, including, but not restricted to vasodila-
tion, platelet aggregation and neurotransmission. Four
sGC subunits named α1, α2, β1 and β2, products of four
independent genes, have been identified in humans. The
α1/β1 sGC heterodimer is the main form expressed in var-
ious tissues and is regarded as the major isoform mediat-
ing vasodilation. We have identified three additional
variants of α1sGC generated by alternative splicing. Oneα1 sGC splice form, named N1-type, codes a 363 amino
acids protein with fully eliminated catalytic domain due
to a 330 amino acid C-terminal deletion. This form also
contains a unique stretch of 3 amino acids at the C-termi-
nus. A second type, named N2-type, codes a protein that
preserved only 126 N-terminal residues and gained addi-
tional 17 unique residues. The third identified splice α1
sGC variant, termed C-type, has a 240 amino acid dele-
tion in the N-terminus, but maintains intact the regula-
tory and catalytic domains [1,2]. RT-PCR analysis of N1,
N2- and C-type α1 sGC mRNA levels indicates that abun-
dance of these splice forms vary in different human tissues
and during differentiation of human embryonic stem
cells. These data indicate that expression of these isoforms
is independently regulated.
Co-expression of C-type α1 sGC variant with full length β1
sGC in Sf9 cells demonstrated that the splice variant het-
erodimerizes with the β1 subunit to produce NO-sensitive
catalytically active enzyme. N1-type α1 sGC co-expressed
at different ratios with α1/β1 sGC in Sf9 cells had domi-
nant negative effects. BE2 human neuroblastoma line was
stably transfected to overexpress N1- or C-type α1 iso-
forms. NO-dependant cGMP production in these lines
was decreased for N1-type and increased for C-type, which
corroborates the results obtained in Sf9 cells.
In summary, our data suggest that alternative splicing of
the α1 subunit is a novel mechanism for sGC regulation in
different human tissues.
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